James Baber

1.5k total citations
13 papers, 349 citations indexed

About

James Baber is a scholar working on Infectious Diseases, Epidemiology and Microbiology. According to data from OpenAlex, James Baber has authored 13 papers receiving a total of 349 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 5 papers in Epidemiology and 5 papers in Microbiology. Recurrent topics in James Baber's work include Antimicrobial Resistance in Staphylococcus (9 papers), Bacterial Infections and Vaccines (5 papers) and Clostridium difficile and Clostridium perfringens research (3 papers). James Baber is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (9 papers), Bacterial Infections and Vaccines (5 papers) and Clostridium difficile and Clostridium perfringens research (3 papers). James Baber collaborates with scholars based in United States, Australia and Germany. James Baber's co-authors include Annaliesa S. Anderson, William C. Gruber, Kathrin U. Jansen, David Cooper, Qin Jiang, Helen Marshall, Edward T. Zito, Michael D. Nissen, Kathrin U. Jansen and Peter Richmond and has published in prestigious journals such as Nature Communications, The Journal of Infectious Diseases and British journal of surgery.

In The Last Decade

James Baber

13 papers receiving 339 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Baber United States	10	190	130	108	102	38	13	349
Corné de Vogel Netherlands	10	70 0.4×	196 1.5×	70 0.6×	101 1.0×	76 2.0×	11	369
T. Perpoint France	9	134 0.7×	79 0.6×	46 0.4×	55 0.5×	45 1.2×	17	313
Douglas Girgenti United States	12	285 1.5×	131 1.0×	189 1.8×	96 0.9×	65 1.7×	15	592
Terri Mininni United States	9	169 0.9×	251 1.9×	137 1.3×	173 1.7×	52 1.4×	11	466
Michaela A. Gazdik United States	13	297 1.6×	187 1.4×	165 1.5×	31 0.3×	17 0.4×	19	460
Tatiana Travis United States	7	135 0.7×	144 1.1×	105 1.0×	19 0.2×	29 0.8×	7	352
Terence K.M. Cheung China	8	91 0.5×	180 1.4×	43 0.4×	37 0.4×	27 0.7×	10	323
Lutz Bader Germany	11	182 1.0×	155 1.2×	134 1.2×	28 0.3×	24 0.6×	19	438
Beatriz Perazzi Argentina	10	98 0.5×	87 0.7×	68 0.6×	92 0.9×	9 0.2×	38	272
Kentaro Nagaoka Japan	10	98 0.5×	103 0.8×	64 0.6×	27 0.3×	23 0.6×	43	326

Countries citing papers authored by James Baber

Since Specialization

Citations

This map shows the geographic impact of James Baber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Baber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Baber more than expected).

Fields of papers citing papers by James Baber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Baber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Baber. The network helps show where James Baber may publish in the future.

Co-authorship network of co-authors of James Baber

This figure shows the co-authorship network connecting the top 25 collaborators of James Baber. A scholar is included among the top collaborators of James Baber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Baber. James Baber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Otsuki, Takeo, Kenzo Kosaka, Iona Munjal, et al.. (2024). Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial. Vaccine. 42(22). 126041–126041. 8 indexed citations

Baber, James, Yuben Moodley, Anna Jaques, et al.. (2022). A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults. The Journal of Infectious Diseases. 226(12). 2054–2063. 27 indexed citations

Haranaka, Miwa, James Baber, Yoichiro Ogama, et al.. (2021). A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications. 12(1). 7105–7105. 23 indexed citations

Marshall, Helen, James Baber, Peter Richmond, et al.. (2019). S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine. Journal of Infection. 79(6). 582–592. 5 indexed citations

Creech, C. Buddy, Robert W. Frenck, Anne Fiquet, et al.. (2019). Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag). Open Forum Infectious Diseases. 7(1). ofz532–ofz532. 14 indexed citations

Inoue, Megumi, James Baber, Yasuko Shoji, et al.. (2018). Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults. Human Vaccines & Immunotherapeutics. 14(11). 1–10. 12 indexed citations

Gurtman, Alejandra, Elizabeth Begier, Naglaa Mohamed, et al.. (2018). The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery. Human Vaccines & Immunotherapeutics. 15(2). 358–370. 16 indexed citations

Mohamed, Naglaa, Ulf Liljenqvist, Ingrid L. Scully, et al.. (2017). Vaccine development to preventStaphylococcus aureussurgical-site infections. British journal of surgery. 104(2). e41–e54. 27 indexed citations

Frenck, Robert W., C. Buddy Creech, Eric Sheldon, et al.. (2016). Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. Vaccine. 35(2). 375–384. 51 indexed citations

10.

Marshall, Helen, Michael D. Nissen, Peter Richmond, et al.. (2016). Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. Journal of Infection. 73(5). 437–454. 9 indexed citations

11.

Creech, C. Buddy, Robert W. Frenck, Eric Sheldon, et al.. (2016). Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. Vaccine. 35(2). 385–394. 43 indexed citations

12.

Nissen, Michael D., Helen Marshall, Peter Richmond, et al.. (2015). A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 33(15). 1846–1854. 50 indexed citations

13.

Marshall, Helen, Peter Richmond, Michael D. Nissen, et al.. (2013). A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 31(12). 1569–1575. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact